HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic relapsing polyradiculoneuropathy in IgG lambda monoclonal gammopathy of undetermined significance (MGUS)--complete remission following carmustine treatment.

Abstract
A previously healthy 43 year-old female developed IgG lambda monoclonal gammopathy of undetermined significance (MGUS) and ascending sensorimotor polyradiculoneuropathy which relapsed 11 times within 2 years. Marked improvement was noted repeatedly after plasmapheresis. However, on each occasion symptoms and signs of polyradiculoneuropathy recurred almost exactly 3 weeks after plasma-pheresis. Following 6 weeks of treatment with carmustine (70 mg/week), nearly complete recovery was established, which has persisted up to now (82 months after the end of therapy). The close temporal correlation between clinical relapse and recurrence of the IgG paraprotein and its permanent absence in stable clinical remission after carmustine treatment suggest a causal relationship between the paraprotein and the polyradiculoneuropathy. However, further studies are required to confirm this observation, as well as the efficacy of carmustine therapy.
AuthorsC Wöber, M Schmidbauer, I Podreka, S Wenger, N Pafflmeyer, L Deecke
JournalWiener klinische Wochenschrift (Wien Klin Wochenschr) Vol. 107 Issue 10 Pg. 318-20 ( 1995) ISSN: 0043-5325 [Print] Austria
PMID7785279 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Immunoglobulin G
  • Immunoglobulin lambda-Chains
  • Prednisolone
  • Carmustine
Topics
  • Adult
  • Carmustine (therapeutic use)
  • Combined Modality Therapy
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G (analysis)
  • Immunoglobulin lambda-Chains (analysis)
  • Neurologic Examination (drug effects)
  • Paraproteinemias (drug therapy, immunology)
  • Plasmapheresis
  • Polyradiculoneuropathy (drug therapy, immunology)
  • Prednisolone (therapeutic use)
  • Recurrence
  • Synaptic Transmission (drug effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: